News

LumaCyte Unveils Predictive CAR T Donor Analytics to Revolutionize Cell Therapy Manufacturing

LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announces the launch of its groundbreaking cell therapy application for predictive CAR T donor analytics. Leveraging its novel Laser Force Cytology™ (LFC™) technology and Radiance® instrument, LumaCyte uncovers deep data insights into highly variable and complex patient and donor cellular starting material, enabling cell therapy developers to predict manufacturing success for specific donors or patients. To ensure that all interested partners can benefit from this powerful new application, LumaCyte has introduced a new donor qualification service where customers can ship donor or patient samples to LumaCyte for analysis and qualification. This service aims to revolutionize the cell therapy landscape by minimizing manufacturing risks due to variability in cellular starting material, enhancing production consistency, and increasing production yields.

The industry has long sought to understand the innate variability across donors and patients and how to predict manufacturing and clinical success based on biomarkers in the cellular starting material. The ability to predict the outcome prior to the start of manufacturing with near real-time analytical insights is considered the holy grail for donor selection. Combining advanced in-process analytics with the ability to enable adaptive manufacturing would be a quantum leap for the immunotherapy industry; Reducing manufacturing failures and compressing time and costs for delivering these lifesaving treatments.

“The biopharmaceutical industry is advancing scientific breakthroughs into the clinic faster than any other time in its history. Developers must think differently from the start to be able to meet the clinical and commercial manufacturing scale required to serve the hundreds of thousands of advanced therapy patients expected by 2030. “We are honored to do our part in providing valuable real-time data insights that have the power to accelerate the time to patient as well as improve the cost and effectiveness of these lifesaving treatments,” says Dr. Sean Hart, LumaCyte CEO and CSO.

Regulatory bodies are increasingly emphasizing adaptive manufacturing and comprehensive qualification of starting materials to ensure consistency and reproducibility. LumaCyte’s new predictive CAR T donor analytics capability addresses these demands with real-time, label-free, quantitative cell characterization. This enables precise and reliable qualification of donor cells, predictive of manufacturing success, and functional potency measurements throughout the process. Starting with high-quality materials helps manufacturers avoid failures and when combined with adaptive manufacturing, can significantly reduce treatment costs and expand patient access.

The introduction of predictive CAR T donor analytics marks a transformative leap for the cell therapy community. Utilizing LumaCyte’s Radiance® platform technology, researchers and manufacturers can achieve unparalleled accuracy and efficiency, ensuring reliability across cellular analysis workflows. This innovation enhances the quality and consistency of CAR T cell therapies while significantly reducing costs, making these life-saving treatments in the future more accessible to patients in need.

 

Learn more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep